{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:17:26Z","timestamp":1792995446170,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003425","name":"Departamento de Educaci\u00f3n, Gobierno de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jhepr.2020.100167","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T21:22:17Z","timestamp":1596748937000},"page":"100167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg"],"prefix":"10.1016","volume":"2","author":[{"given":"Maite G.","family":"Fern\u00e1ndez-Barrena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4830-1924","authenticated-orcid":false,"given":"Mar\u00eda","family":"Arechederra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7403-9149","authenticated-orcid":false,"given":"Leticia","family":"Colyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-2476","authenticated-orcid":false,"given":"Carmen","family":"Berasain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-3557","authenticated-orcid":false,"given":"Matias A.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2020.100167_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib2","article-title":"Epidemiology of hepatocellular carcinoma","author":"McGlynn","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib3","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1158\/0008-5472.CAN-19-0803","article-title":"Recent developments and therapeutic strategies against hepatocellular carcinoma","volume":"79","author":"Yarchoan","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/cancers11111677","article-title":"Models for understanding resistance to chemotherapy in liver cancer","volume":"11","author":"Marin","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2020.100167_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/gutjnl-2017-315068","article-title":"Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma","volume":"67","author":"Gerbes","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100167_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2017.09.007","article-title":"Targets for immunotherapy of liver cancer","volume":"68","author":"Greten","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/gutjnl-2019-319720","article-title":"Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting","volume":"69","author":"Avila","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100167_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ng.2291","article-title":"Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators","volume":"44","author":"Fujimoto","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Ally","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.05.035","article-title":"Genetic profiling of hepatocellular carcinoma using next-generation sequencing","volume":"65","author":"Schulze","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2018.11.001","article-title":"Genomic medicine and implications for hepatocellular carcinoma prevention and therapy","volume":"156","author":"Dhanasekaran","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","article-title":"Advances in molecular classification and precision oncology in hepatocellular carcinoma","volume":"72","author":"Rebouissou","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ng.903","article-title":"Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma","volume":"43","author":"Li","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer \u2014 biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib24","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/hep.26540","article-title":"Identification of driver genes in hepatocellular carcinoma by exome sequencing","volume":"58","author":"Cleary","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib25","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gr.154492.113","article-title":"Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma","volume":"23","author":"Kan","year":"2013","journal-title":"Genome Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2019.03.007","article-title":"A\u00a0comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets","volume":"71","author":"Bayo","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib27","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib29","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrd.2016.256","article-title":"Marked for death: targeting epigenetic changes in cancer","volume":"16","author":"Pfister","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhepr.2020.100167_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ccell.2016.03.007","article-title":"Exploiting the epigenome to control cancer-promoting gene-expression programs","volume":"29","author":"Brien","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tig.2020.05.002","article-title":"Unraveling the epigenetic basis of liver development, regeneration and disease","volume":"36","author":"Macchi","year":"2020","journal-title":"Trends Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semcdb.2019.03.004","article-title":"Chromatin dynamics during liver regeneration","volume":"97","author":"Arechederra","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2020.100167_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cbpa.2020.04.008","article-title":"Towards a more precise therapy in cancer: exploring epigenetic complexity","volume":"57","author":"Coss\u00edo","year":"2020","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib37","doi-asserted-by":"crossref","first-page":"e12791","DOI":"10.1111\/cpr.12791","article-title":"The roles of mutated SWI\/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: a review","volume":"53","author":"Hu","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jhepr.2020.100167_bib38","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cancers12051243","article-title":"Non-coding RNAs: regulating disease progression and therapy resistance in hepatocellular carcinoma","volume":"12","author":"Manna","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2020.100167_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40169-019-0230-0","article-title":"Epigenetics of hepatocellular carcinoma","volume":"8","author":"Toh","year":"2019","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrm.2017.47","article-title":"Understanding nucleosome dynamics and their links to gene expression and DNA replication","volume":"18","author":"Lai","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm4043","article-title":"DNA methylation pathways and their crosstalk with histone methylation","volume":"16","author":"Du","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib42","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/genes9110566","article-title":"Molecular processes connecting DNA methylation patterns with DNA methyltransferases and histone modifications in mammalian genomes","volume":"9","author":"Jeltsch","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jhepr.2020.100167_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","article-title":"Gene body methylation can alter gene expression and is a therapeutic target in cancer","volume":"26","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1870-5","article-title":"Epigenetic modifications of histones in cancer","volume":"20","author":"Zhao","year":"2019","journal-title":"Genome Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1874467212666190215112915","article-title":"Targeting chromatin remodeling for cancer therapy","volume":"12","author":"Kaur","year":"2019","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.jhepr.2020.100167_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","article-title":"Lateral thinking: how histone modifications regulate gene expression","volume":"32","author":"Lawrence","year":"2016","journal-title":"Trends Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2018.08.021","article-title":"Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy","volume":"837","author":"Biswas","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jhepr.2020.100167_bib50","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1038\/onc.2017.201","article-title":"Signaling coupled epigenomic regulation of gene expression","volume":"36","author":"Kumar","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2020.100167_bib51","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1096\/fj.00-0556fjev1","article-title":"Hepatocyte growth factor induces MAT2A expression and histone acetylation in rat hepatocytes: role in liver regeneration 1","volume":"15","author":"Latasa","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.jhepr.2020.100167_bib52","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/cells9040878","article-title":"MeCP2 and chromatin compartmentalization","volume":"9","author":"Schmidt","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2020.100167_bib53","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1021\/acschembio.5b00830","article-title":"Reading between the lines: \u201caDD\u201d-ing histone and DNA methylation marks toward a new epigenetic \u201csum\u201d","volume":"11","author":"Noh","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.molcel.2016.05.004","article-title":"Greater than the sum of parts: complexity of the dynamic epigenome","volume":"62","author":"Soshnev","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib55","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.molcel.2017.07.012","article-title":"Methylation of DNA ligase 1 by G9a\/GLP recruits UHRF1 to replicating DNA and regulates DNA methylation","volume":"67","author":"Ferry","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrg.2017.33","article-title":"TET-mediated active DNA demethylation: mechanism, function and beyond","volume":"18","author":"Wu","year":"2017","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhepr.2020.100167_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhepr.2020.100167_bib58","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jmb.2019.07.039","article-title":"Protein interactions at oxidized 5-methylcytosine bases","volume":"432","author":"Pfeifer","year":"2020","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jhepr.2020.100167_bib59","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib60","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.jhepr.2020.100167_bib61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/genes9120617","article-title":"Mechanisms of DNA methyltransferase recruitment in mammals","volume":"9","author":"Laisn\u00e9","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jhepr.2020.100167_bib62","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/cancers11101524","article-title":"LncRNAs as chromatin regulators in cancer: From molecular function to clinical potential","volume":"11","author":"Begolli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2020.100167_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmet.2020.04.022","article-title":"A\u00a0metabolic roadmap for somatic stem cell fate","volume":"31","author":"Ly","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2020.100167_bib64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.gendis.2019.09.012","article-title":"Metabolic reprogram associated with epithelial-mesenchymal transition in tumor progression and metastasis","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis"},{"key":"10.1016\/j.jhepr.2020.100167_bib65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13148-020-00862-0","article-title":"Symphony of epigenetic and metabolic regulation - interaction between the histone methyltransferase EZH2 and metabolism of tumor","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jhepr.2020.100167_bib66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/cancers11010061","article-title":"Reading cancer: chromatin readers as druggable targets for cancer treatment","volume":"11","author":"Mio","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2020.100167_bib67","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/molecules25030578","article-title":"Small molecules targeting the specific domains of histone-mark readers in cancer therapy","volume":"25","author":"Zhu","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jhepr.2020.100167_bib68","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/carcin\/bgm206","article-title":"Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state","volume":"28","author":"Kanai","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhepr.2020.100167_bib69","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ijc.26061","article-title":"Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage","volume":"129","author":"Nagashio","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhepr.2020.100167_bib70","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jhep.2010.08.021","article-title":"Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis","volume":"54","author":"Um","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib71","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/hep.25706","article-title":"Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma","volume":"56","author":"Nishida","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib72","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.18632\/oncotarget.2444","article-title":"Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis","volume":"5","author":"Hlady","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2020.100167_bib73","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/onc.2016.340","article-title":"A\u00a0pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets","volume":"36","author":"Wijetunga","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2020.100167_bib74","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/carcin\/bgx005","article-title":"Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis","volume":"38","author":"Kuramoto","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhepr.2020.100167_bib75","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2019.09.005","article-title":"Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas","volume":"157","author":"Ding","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib76","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1172\/JCI31457","article-title":"Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma","volume":"117","author":"Calvisi","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2020.100167_bib77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/epi.23062","article-title":"Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips","volume":"8","author":"Shen","year":"2013","journal-title":"Epigenetics"},{"key":"10.1016\/j.jhepr.2020.100167_bib78","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.27732","article-title":"DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma","volume":"61","author":"Villanueva","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib79","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41467-018-03999-y","article-title":"Epigenetic landscape influences the liver cancer genome architecture","volume":"9","author":"Hama","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2020.100167_bib80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41467-018-08245-z","article-title":"Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming","volume":"10","author":"Xiong","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2020.100167_bib81","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1053\/j.gastro.2013.08.055","article-title":"Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma","volume":"145","author":"Revill","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib82","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/138920211795564359","article-title":"Genetic and epigenetic signatures in human hepatocellular carcinoma:A systematic review","volume":"12","author":"Nishida","year":"2011","journal-title":"Curr Genomics"},{"key":"10.1016\/j.jhepr.2020.100167_bib83","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0168-8278(00)80122-1","article-title":"Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma","volume":"33","author":"Avila","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib84","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/0008-5472.CAN-15-2601","article-title":"Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma","volume":"76","author":"Hirata","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib85","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajpath.2010.10.023","article-title":"DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma","volume":"178","author":"Liu","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2020.100167_bib86","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1038\/s41467-018-05550-5","article-title":"Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer","volume":"9","author":"Arechederra","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2020.100167_bib87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13073-018-0548-z","article-title":"Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers","volume":"10","author":"Cheng","year":"2018","journal-title":"Genome Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib88","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ebiom.2019.08.064","article-title":"Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma","volume":"47","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2020.100167_bib89","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1053\/j.gastro.2008.07.027","article-title":"Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter","volume":"135","author":"Lim","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib90","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1053\/j.gastro.2007.01.034","article-title":"Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein","volume":"132","author":"Park","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib91","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2013.10.056","article-title":"Hepatitis virus infection affects DNA methylation in mice with humanized livers","volume":"146","author":"Okamoto","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib92","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ijc.11127","article-title":"Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas","volume":"105","author":"Saito","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhepr.2020.100167_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ccr.2014.01.003","article-title":"UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma","volume":"25","author":"Mudbhary","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib94","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep.30168","article-title":"Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma","volume":"69","author":"B\u00e1rcena-Varela","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib95","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/jhep.2001.22507","article-title":"Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis","volume":"33","author":"Saito","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib96","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/hep.27823","article-title":"Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate","volume":"62","author":"Udali","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib97","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/hep.30211","article-title":"Integrating the epigenome to identify drivers of hepatocellular carcinoma","volume":"69","author":"Hlady","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib98","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.30146","article-title":"Global DNA 5-hydroxymethylcytosine and 5-formylcytosine contents are decreased in the early stage of hepatocellular carcinoma","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib99","doi-asserted-by":"crossref","first-page":"e12626","DOI":"10.1111\/cpr.12626","article-title":"Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma","volume":"52","author":"Wang","year":"2019","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jhepr.2020.100167_bib100","doi-asserted-by":"crossref","first-page":"e2906","DOI":"10.1038\/cddis.2017.142","article-title":"MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis","volume":"8","author":"Chen","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2020.100167_bib101","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/liv.14381","article-title":"The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma","volume":"40","author":"Pot\u00e9","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2020.100167_bib102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-011-1103-0","article-title":"Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC","volume":"459","author":"Quint","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jhepr.2020.100167_bib103","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3892\/or.2015.4263","article-title":"HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population","volume":"34","author":"Ler","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jhepr.2020.100167_bib104","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/hep.26101","article-title":"Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/17474124.2019.1568870","article-title":"Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer","volume":"13","author":"Zhao","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib106","doi-asserted-by":"crossref","first-page":"52357","DOI":"10.18632\/oncotarget.14096","article-title":"Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2020.100167_bib107","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/hep.26278","article-title":"SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B\/glycogen synthase kinase-3\u03b2\/\u03b2-catenin signaling","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib108","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1158\/0008-5472.CAN-14-3786","article-title":"Histone deacetylase HDAC8 promotes insulin resistance and \u03b2-catenin activation in NAFLD-associated hepatocellular carcinoma","volume":"75","author":"Tian","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib109","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3346\/jkms.2015.30.10.1375","article-title":"Histone deacetylases and their regulatory microRNAs in hepatocarcinogenesis","volume":"30","author":"Kim","year":"2015","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.jhepr.2020.100167_bib110","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1158\/0008-5472.CAN-13-3531","article-title":"Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2","volume":"74","author":"Lee","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib111","doi-asserted-by":"crossref","first-page":"43864","DOI":"10.1038\/srep43864","article-title":"Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2020.100167_bib112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11684-013-0253-7","article-title":"Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins","volume":"7","author":"Au","year":"2013","journal-title":"Front Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib113","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/0008-5472.CAN-10-3342","article-title":"EZH2-mediated concordant repression of Wnt antagonists promotes \u03b2-catenin-dependent hepatocarcinogenesis","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib114","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.25679","article-title":"Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis","volume":"56","author":"Au","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib115","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jhep.2014.11.040","article-title":"A\u00a0CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients","volume":"62","author":"Feng","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib116","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/hep.26083","article-title":"Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b","volume":"57","author":"Ngo-Yin Fan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib117","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.28304","article-title":"Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib118","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2017.05.015","article-title":"Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3","volume":"67","author":"Wei","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib119","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1245\/s10434-011-1797-x","article-title":"Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection","volume":"19","author":"Yamada","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib120","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.3748\/wjg.v18.i45.6651","article-title":"Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients","volume":"18","author":"Zhao","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2020.100167_bib121","doi-asserted-by":"crossref","first-page":"34320","DOI":"10.18632\/oncotarget.26144","article-title":"Overexpression of KDM5B\/JARID1B is associated with poor prognosis in hepatocellular carcinoma","volume":"9","author":"Shigekawa","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2020.100167_bib122","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1158\/0008-5472.CAN-15-3029","article-title":"Aberrant JMJD3 expression upregulates slug to promote migration, invasion, and stem cell-like behaviors in hepatocellular carcinoma","volume":"76","author":"Tang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib123","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.acthis.2014.10.002","article-title":"JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study","volume":"117","author":"Lu","year":"2015","journal-title":"Acta Histochem"},{"key":"10.1016\/j.jhepr.2020.100167_bib124","doi-asserted-by":"crossref","first-page":"102676","DOI":"10.1016\/j.ebiom.2020.102676","article-title":"ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation","volume":"53","author":"Lin","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2020.100167_bib125","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/0008-5472.CAN-14-1560","article-title":"Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells","volume":"75","author":"Sakamoto","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2020.100167_bib126","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1038\/onc.2015.129","article-title":"Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5\u00a0+ liver cancer initiating cells by suppressing negative regulators of \u03b2-catenin signaling","volume":"34","author":"Lei","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2020.100167_bib127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0394632015572070","article-title":"BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"28","author":"Zhang","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jhepr.2020.100167_bib128","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/hep.30544","article-title":"Aberrant super-enhancer landscape in human hepatocellular carcinoma","volume":"69","author":"Tsang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib129","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","article-title":"The future of epigenetic therapy in solid tumours - lessons from the past","volume":"10","author":"Azad","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","article-title":"Targeting epigenetics in cancer","volume":"58","author":"Bennett","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jhepr.2020.100167_bib131","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41416-020-0823-9","article-title":"Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential","volume":"122","author":"Tsui","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2020.100167_bib132","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2020.100167_bib133","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fonc.2015.00134","article-title":"Episensitization: defying time's arrow","volume":"5","author":"Oronsky","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib134","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.7150\/thno.42523","article-title":"Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer","volume":"10","author":"Ravindran Menon","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jhepr.2020.100167_bib135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhepr.2020.100167_bib136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","article-title":"A\u00a0clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jhepr.2020.100167_bib138","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jhepr.2020.100167_bib139","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clml.2018.05.007","article-title":"Optimal management of histone deacetylase inhibitor-related adverse events in patients with multiple myeloma: a focus on panobinostat","volume":"18","author":"Cavenagh","year":"2018","journal-title":"Clin lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jhepr.2020.100167_bib140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.07.001","article-title":"Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/S\u00e9zary syndrome): use in a community setting","volume":"106","author":"Reddy","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jhepr.2020.100167_bib141","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-An overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib142","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3892\/or.2017.5722","article-title":"Targeting the PD-L1\/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma","volume":"38","author":"Liu","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jhepr.2020.100167_bib143","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.ymthe.2018.04.018","article-title":"Differentiation therapy by epigenetic reconditioning exerts antitumor effects on liver cancer cells","volume":"26","author":"Gailhouste","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2020.100167_bib144","doi-asserted-by":"crossref","first-page":"16698","DOI":"10.18632\/oncotarget.3677","article-title":"An open-label, single-arm, phase I\/II study of lowerdose decitabine based therapy in patients with advanced hepatocellular carcinoma","volume":"6","author":"Mei","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2020.100167_bib145","doi-asserted-by":"crossref","first-page":"54ra77","DOI":"10.1126\/scitranslmed.3001338","article-title":"An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer","volume":"2","author":"Andersen","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib146","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.molonc.2015.06.002","article-title":"Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin","volume":"9","author":"Kuang","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib147","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/15592294.2016.1214781","article-title":"Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma","volume":"11","author":"Jueliger","year":"2016","journal-title":"Epigenetics"},{"key":"10.1016\/j.jhepr.2020.100167_bib148","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/hep.30091","article-title":"Integrative epigenetic analysis reveals therapeutic targets to the DNA methyltransferase inhibitor guadecitabine (SGI-110) in hepatocellular carcinoma","volume":"68","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2020.100167_bib149","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","article-title":"Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model","volume":"68","author":"Llopiz","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhepr.2020.100167_bib150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2016.02.043","article-title":"Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma \u2013 the SHELTER study","volume":"65","author":"Bitzer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib151","doi-asserted-by":"crossref","first-page":"110367","DOI":"10.18632\/oncotarget.22775","article-title":"Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenibinduced apoptosis","volume":"8","author":"Soukupova","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2020.100167_bib152","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.gastro.2019.10.025","article-title":"Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via MEF2D regulation of programmed cell death 1 ligand 1 in hepatocellular carcinoma cells","volume":"158","author":"Xiang","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib153","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s12325-020-01379-x","article-title":"The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review","volume":"37","author":"Rugo","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jhepr.2020.100167_bib154","doi-asserted-by":"crossref","first-page":"E3509","DOI":"10.1073\/pnas.1802691115","article-title":"Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells","volume":"115","author":"Bugide","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2020.100167_bib155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cellimm.2018.12.010","article-title":"Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma","volume":"336","author":"Hong","year":"2019","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jhepr.2020.100167_bib156","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2019.01.250","article-title":"Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in mice","volume":"156","author":"Wei","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2020.100167_bib157","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2017.03.038","article-title":"Targeting KDM1A attenuates Wnt\/\u03b2-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma","volume":"398","author":"Huang","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhepr.2020.100167_bib158","doi-asserted-by":"crossref","first-page":"15424","DOI":"10.1038\/ncomms15424","article-title":"Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies","volume":"8","author":"San Jos\u00e9-En\u00e9riz","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2020.100167_bib159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.onc.1209763","article-title":"5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation","volume":"26","author":"Wozniak","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2020.100167_bib160","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","article-title":"Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"25","author":"Segovia","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2020.100167_bib161","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2020.100167_bib162","article-title":"Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma","author":"J\u00fchling","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100167_bib163","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/gutjnl-2018-317257","article-title":"Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma","volume":"69","author":"Liu","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100167_bib164","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcmgh.2017.04.007","article-title":"Epigenetics and liver fibrosis","volume":"4","author":"Moran-Salvador","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2020.100167_bib165","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3390\/ijms20102507","article-title":"Epigenetic mechanisms in hepatic stellate cell activation during liver fibrosis and carcinogenesis","volume":"20","author":"Barcena-Varela","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2020.100167_bib166","doi-asserted-by":"crossref","first-page":"15713","DOI":"10.1073\/pnas.1522163112","article-title":"BRD4 is a novel therapeutic target for liver fibrosis","volume":"112","author":"Ding","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2020.100167_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2019-320205","article-title":"Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis","author":"Barcena-Varela","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2020.100167_bib168","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibs.2020.02.006","article-title":"Gene-specific actions of transcriptional coregulators facilitate physiological plasticity: evidence for a physiological coregulator code","volume":"45","author":"Stallcup","year":"2020","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jhepr.2020.100167_bib169","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours \u2014 past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","article-title":"The timeline of epigenetic drug discovery: from reality to dreams","volume":"11","author":"Ganesan","year":"2019","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jhepr.2020.100167_bib171","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cncr.29175","article-title":"Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma","volume":"121","author":"Choy","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2020.100167_bib172","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2020.100167_bib173","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1634\/theoncologist.2019-0671","article-title":"Managing hyperprogressive disease in the era of programmed cell death protein 1\/programmed death-ligand 1 blockade: a case discussion and review of the literature","volume":"25","author":"Grecea","year":"2020","journal-title":"Oncologist"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555920301014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555920301014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:24:56Z","timestamp":1762899896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555920301014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2589555920301014"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2020.100167","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2020.100167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100167"}}